SynthesisCritical care (London, England)2018
Systematic review of incretin therapy during peri-operative and intensive care.
Synthesis in Critical care (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- [Hospital diabetes management (Update 2026)].Wiener klinische Wochenschrift · 2026Guideline
- Enteral nutrition-related hyperglycemia in critical illness: cascade conceptual model and implications for precision nursing-a systematic review.Frontiers in nutrition · 2026Pooled it
- Guideline
- Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial.Diabetes, obesity & metabolism · 2020 · on this mapTrial
- What Are the Impacts of GLP-1 Drugs in Patients Needing Head/Neck Surgery?The Laryngoscope · 2026Article
- Diabetes Management Strategies in Intensive Care Settings.The Medical clinics of North America · 2026Review
- Glucagon-like-peptide-1 receptor agonists in the intensive care unit: practical implications for the intensivists.Critical care science · 2026Article
- Effects of glucagon-like peptide-1 on systemic hemodynamics, kidney function, and intrarenal oxygenation in sheep with sepsis-associated acute kidney injury.Scientific reports · 2025Article
- Engineered Clostridium butyricum: a promising application of synthetic biology in comprehensive health.Microbial cell factories · 2025Review
- Preoperative liraglutide modulates control of fat and glucose metabolism during cardiopulmonary bypass surgery.Endocrine connections · 2025Article
- Glucagon-Like Peptide-1 Is Prognostic of Mortality in Acute Respiratory Failure.Critical care explorations · 2025Article
- A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia.Journal of anesthesia, analgesia and critical care · 2025Review
- Glucagon-Like Peptide-1 Receptor Agonist Use is Not Associated With Increased Complications After Total Knee Arthroplasty in Patients With Type-2 Diabetes.Arthroplasty today · 2024Article
- Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2024Article
- Review
- Neuroprotective effect of engineeredBioengineering & translational medicine · 2023Article
- Prognostic Significance of Plasma Insulin Level for Deep Venous Thrombosis in Patients with Severe Traumatic Brain Injury in Critical Care.Neurocritical care · 2023Observational
- COVID-19: Diabetes Perspective-Pathophysiology and Management.Pathogens (Basel, Switzerland) · 2023Review
- [Position statement: surgery and diabetes mellitus (Update 2023)].Wiener klinische Wochenschrift · 2023Article
- Type 2 Diabetes Mellitus and COVID-19: A Narrative Review.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are incretin hormones. By lowering blood glucose in a glucose-dependent manner, incretin-based therapies represent a novel and promising intervention to treat hyperglycaemia in hospital settings. We performed a systematic review of the literature for all current applications of incretin-based therapies in the peri-operative and critical care settings.
methodsWe searched MEDLINE, the Cochrane Library, and Embase databases for all randomised controlled trials using exogenous GLP-1, GLP-1 receptor agonists, exogenous GIP and dipeptidyl peptidase IV inhibitors in the setting of adult peri-operative care or intensive care. We defined no comparator treatment. Outcomes of interest included blood glucose, frequency of hypoglycaemia and insulin administration.
resultsOf the 1190 articles identified during the initial literature search, 38 fulfilled criteria for full-text review, and 19 single-centre studies were subsequently included in the qualitative review. Of the 18 studies reporting glycaemic control, improvement was reported in 15, defined as lower glucose concentrations in 12 and as reduced insulin administration (with similar glucose concentrations) in 3. Owing to heterogeneity, meta-analysis was possible only for the outcome of hypoglycaemia. This revealed an incidence of 7.4% in those receiving incretin-based therapies and 6.8% in comparator groups (P = 0.94).
conclusionsIn small, single-centre studies, incretin-based therapies lowered blood glucose and reduced insulin administration without increasing the incidence of hypoglycaemia.
trial registrationPROSPERO, CRD42017071926.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.